HPV Vaccine Dosing Schedule
For both Gardasil 4 (quadrivalent) and Gardasil 9 (nonavalent), the dosing schedule depends on the age at which vaccination is initiated: individuals starting vaccination before age 15 receive a 2-dose schedule (0,6-12 months), while those starting at age 15 or older require a 3-dose schedule (0,1-2,6 months). 1, 2, 3
Age-Based Dosing Schedules
Ages 9-14 Years
- 2-dose schedule: Doses given at 0 and 6-12 months apart
- Important caveat: If the second dose is administered earlier than 5 months after the first dose, a third dose must be given at least 4 months after the second dose 2, 3
Ages 15-26 Years
Ages 27-45 Years
- 3-dose schedule if vaccination is pursued
- Vaccination in this age group requires shared clinical decision-making, as it is not routinely recommended for all adults over 26 1
- Population benefit is minimal due to prior HPV exposure, though some individuals at risk for new infections may benefit
Special Populations
Immunocompromised Individuals (Including HIV)
- Always use 3-dose schedule regardless of age at vaccination initiation 1
- This applies to all persons with immunocompromising conditions
Key Clinical Considerations
Minimum intervals are critical: When an abbreviated schedule is necessary, ensure a minimum of 24 weeks between the first and last dose in either a 2-dose or 3-dose schedule 4. However, efforts should be made to adhere to recommended intervals rather than minimum intervals, as optimal immunogenicity data supports the standard schedules.
No difference between Gardasil 4 and Gardasil 9 schedules: Both vaccines follow identical dosing schedules based on age and immune status 2, 3. The nonavalent vaccine provides additional protection against HPV types 31,33,45,52, and 58 beyond the quadrivalent vaccine's coverage.
Two-dose non-inferiority: Evidence demonstrates that 2-dose schedules in younger adolescents (ages 9-14) produce antibody responses comparable to 3-dose schedules, with immunogenicity maintained for up to 5-11 years 5, 6. This is why the age cutoff at 15 years is used to determine dosing schedules.
No pre-vaccination testing needed: Do not perform Pap testing or HPV testing before vaccination to determine appropriateness 1.
Cervical cancer screening continues: HPV vaccination does not eliminate the need for routine cervical cancer screening per standard guidelines 1, 2, 3.